MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201 Recall
MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201
FDA recall Class II
Ongoing
FDA lists this Class II recall for MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201. Review the affected identifiers, reported reason and manufacturer instructions below.
Recall at a glance
- Recall number
- Z-3133-2026
- Recall classification
- Class II
- Enforcement status
- Ongoing
- Initiation date
- Aug 5, 2026
- FDA report date
- Sep 16, 2026
- Quantity in commerce
- 3,286 cases
- Distribution
- See key details
- FDA cause
- Process control
What is being recalled?
MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201
Affected model & UDI checker
Search the exact identifiers published for Z-3133-2026.
The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.
Affected products
| Model / catalog number | Product | Lot scope reported | UDI / GTIN |
|---|---|---|---|
| BC-100 | MedicaLyte Liquid Bicarbonate Concentrate REF: BC-100 and BC+201 | Check source notice | Not specified |
FDA code information
BC-100 - Lot:N4L022 (exp.11/13/2026), N4L037(exp.11/18/2026) BC+201- Lot: N4L010(exp.11/06/2026)
Why was this product recalled?
Hemodialysis concentrates contain high endotoxin levels
What actions did Nipro Renal Soultions USA, Corporation take?
On August 6, 2026 Nipro Medical Corporation issued a Urgent Medical Device Recall notification via Email. Nipro asked consignees to take the following actions: 1. Immediately examine your inventory for the affected product codes and lot numbers listed on the Recall response form. 2. Immediately segregate, quarantine, and discontinue use or distribution of any affected product in your possession. 3. Do not use, sell, transfer, or distribute affected products. 4. Complete the enclosed Recall Response Form within 10 business days, even if you do not have affected product on hand. 5. Contact Nipro customer service for product return and credit, if applicable. 6. If you distributed affected product, promptly notify your customers, provide them with a copy of this recall notice, and request that they complete and return the response form or equivalent confirmation. 7. Product Return or Disposition: Affected products should remain quarantined until return, destruction, or other documented disposition instructions are provided by Nipro. Please retain all documentation related to product quarantine, return, destruction, or other disposition for recall reconciliation.
Read the manufacturer action recorded by FDARecall timeline
Recall initiated by firm
FDA notice posted
FDA classification recorded
FDA enforcement report date
Related FDA submissions
No submission number with an exact verified relationship is linked in the retrieved recall notice.
FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.
Source and update history
- FDA recall notice Z-3133-2026
- openFDA enforcement record · Source release Nov 11, 2026 · Retrieved Nov 21, 2026
- openFDA device recall record · Source release Nov 19, 2026 · Retrieved Nov 21, 2026
- FDA enforcement data
First stored snapshot of this source.
- FDA device-recall notice
First stored snapshot of this source.
The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.
Our data sources and methodology